

References

I-206

1. Zolgensma® (onasemnogene abeparvovec-xioi) injection, for intravenous use [package insert]. AveXis, Inc. Bannockburn, IL. 2019.
2. Hayes, Inc. Hayes Prognosis Overview. Zolgensma (Onasemnogene Abeparvovec) for Spinal Muscular Atrophy. Landsdale, PA: Hayes, Inc.; February 2019.
3. Mendell J, Al-Zaidy S, Shell R, et.al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med*. 2017;377:1713-1722.
4. Al-Zaidy S, Pickard A, Kotha K, et. al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol*. 2019;54(2):179-185.